ASX:NYR

Nyrada (NYR) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free NYR Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 65,000 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Nyrada alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Nyrada

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurodegenerative diseases. Its products in the drug development stage includes PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; and neuroprotectant drug to reduce the disability in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Gordon, Australia.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

NYR Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive NYR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nyrada and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:NYR
CUSIP: N/A
CIK: N/A
Web: www.nyrada.com
Phone: 61 2 9053 1990
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($0.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,980,000.00
Net Margins: -169.82%
Pretax Margin: N/A
Return on Equity: -72.31%
Return on Assets: -40.53%

Debt

Debt-to-Equity Ratio: 10.10
Current Ratio: 10.92
Quick Ratio: 25.18

Sales & Book Value

Annual Sales: $2.93 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 16.50
Book Value: A$0.03 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 179,410,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 1.54

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. James Bonnar
Chief Executive Officer
Mr. Cameron Jones C.A.
Chief Financial Officer
Mr. Benjamin Evison Ph.D.
Chief Scientific Officer
Mr. Dimitri Burshtein
Investor Relations Manager
Mr. Mark Waring B.Sc.
P.M.P., Senior Vice President of US Operations
Mr. David James Franks BEc (Age 54)
C.A., F Fin, J.P., Company Secretary

Key Competitors

View All Competitors

Insiders

Christopher Cox
Sold 600,000 shares
Total: $60,000.00 ($0.10/share)

This page (ASX:NYR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Nyrada (NYR) Stock Price, News & Analysis

About Nyrada

NYR Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info